WHAT IS CLAIMED IS:

1. A compound according to Formula (I):



(I)

or stereoisomers, tautomers, a pharmaceutically acceptable salts, or solvates thereof, wherein

R_2 is independently selected from H and C_{1-4} alkyl substituted with 1-5 R_9;

R_{13} is independently selected from H, D, and C_{1-4} alkyl substituted with 1-3 R_9;

R_3 and R_4 are independently selected from H, C_{1-7} alkyl substituted with 1-3 R_9, -$(CR_7R_7)_r$-C_{3-8} cycloalkyl substituted with 1-3 R_8, -$(CR_7R_7)_r$-aryl substituted with 1-3 R_8, C_{2-7}alkenyl substituted with 1-3 R_9, -$(CR_7R_7)_r$-5-6 membered heterocyclic ring substituted with 1-3 R_8, -$(CR_7R_7)_r$-5-6 membered heteroaryl ring substituted with 1-3 R_8, or R_3 and R_4 combine with the N to which they are attached to form a 4-9 membered heterocyclic ring substituted with 1-3 R_8;

X^1, X^2, X^3, and X^4 are independently selected from CR_5 and N; provided no more than two of X^1, X^2, X^3, or X^4 are N;

R_5 is independently selected from H, F, Cl, OR_7, CN, $N(R_7)_2$, C_{1-4} alkyl substituted with 1-5 R_9, C_{1-4} alkoxy substituted with 1-5 R_9, and C_{1-4} heteroalkyl substituted with 1-5 R_9;

R_6 is C_{3-8} cycloalkyl which is substituted with R_{10} and $(–CH_2)_{0-1}R_{11}$;

R_7 is independently selected from H, C_{1-4} alkyl, and C_{3-6} cycloalkyl; or R_7 and R_7, together with the carbon atom to which they both attach, form a C_{3-6} cycloalkyl ring;

R_8 is independently selected from H, D, C_{1-6} alkyl substituted with 1-5 R_9, C_{2-6} alkenyl, C_{2-6} alkynyl, phenyl, -$(CH_2)_r$-C_{3-6} cycloalkyl, F, Cl, Br, CN, COOH, and C_{1-4} alkoxy;

R_9 is independently selected from H, D, F, Cl, NH_2, OH, OC_{1-5}alkyl, C_{1-5}alkyl, C_{1-5} heteroalkyl C_{3-6} cycloalkyl, and phenyl, wherein when R_9 is Cl, NH_2 or OH it is not substituted on C_1 of the the alkyl to which it is attached;

R_{10} is independently selected from H, D, C_{1-4} alkyl, F, Cl, Br, OR_7, NHC(=O)OR_7, and NHC(=O)OR_7;

R_{11} is independently selected from H, CN, –C(=O)R_{12}, tetrazolyl,  , and  ;

R_{12} is independently selected from OH, OC_{1-4} alkyl, NH_2, $NHCH_2CH_2SO_3H$, and $NHSO_2C_{1-4}$alky;

r is independently selected from zero, 1, 2, 3, and 4,

and n is slected from 1, 2, 3, or 4.

2. The compound of claim 1, wherein

R_3 and R_4 are independently selected from H, C_{1-7} alkyl substituted with 1-3 R_9, -$(CR_7R_7)_r$-C_{3-8} cycloalkyl substituted with 1-3 R_8, -$(CR_7R_7)_r$-aryl substituted with 1-3 R_8, C_{2-7}alkenyl substituted with 1-3 R_9, -$(CR_7R_7)_r$-5-6 membered heterocyclic ring substituted with 1-3 R_8, -$(CR_7R_7)_r$-5-6 membered heteroaryl ring substituted with 1-3 R_8, and R_3 and R_4 combine with the N to which they are attached to form the following:





substituted with 1-3 R_8, and

n equals 1 or 2.

3. The compound according to claim 1 wherein,

R_3 and R_4 are independently selected from H, C_{1-7} alkyl substituted with 1-3 R_9, -$(CR_7R_7)_r$-C_{3-8} cycloalkyl substituted with 1-3 R_8, -$(CR_7R_7)_r$-aryl substituted with 1-3 R_8, C_{2-7}alkenyl substituted with 1-3 R_9,





, each of which can be substituted with 1-3 R_8, and R_3 and R_4 combine with the N to which they are attached to form a 4-9 membered heterocyclic ring substituted with 1-3 R_8; and

n equals 1 or 2.

4. A compound according to claim 1 of Formula (II):



(II)

or an enantiomer, a diastereomer, a stereoisomer, a pharmaceutically acceptable salt thereof, wherein

R_2 is independently selected from H and C_{1-4} alkyl substituted with 1-5 R_9;

R_{13} is independently selected from H, D, and C_{1-4} alkyl substituted with 1-3 R_9;

R_3 and R_4 are independently selected from H, C_{1-7} alkyl substituted with 1-3 R_9, -$(CR_7R_7)_r$-C_{3-6} cycloalkyl substituted with 1-3 R_8, and -$(CR_7R_7)_r$-aryl substituted with 1-3 R_8;

X^1, X^2, X^3, and X^4 are independently selected from CR_5 and N; provided no more than two of X^1, X^2, X^3, or X^4 are N;

R_5 is independently selected from H, F, Cl, OR_7, CN, $N(R_7)_2$, C_{1-4} alkyl substituted with 1-5 R_9, C_{1-4} alkoxy substituted with 1-5 R_9, and C_{1-4} heteroalkyl substituted with 1-5 R_9;

R_6 is  ;

R_7 is independently selected from H, C_{1-4} alkyl, and C_{3-6} cycloalkyl; or R_7 and $R_{7,}$ together with the carbon atom to which they both attach, form a C_{3-6} cycloalkyl ring;

R_8 is independently selected from H, C_{1-6} alkyl substituted with 1-5 R_9, C_{2-6} alkenyl, C_{2-6} alkynyl, -$(CH_2)_r$-C_{3-6} cycloalkyl, F, Cl, Br, CN, and COOH;

R_9 is independently selected from H, F, Cl, NH_2, OH, OC_{1-5}alkyl, C_{1-5}alkyl, C_{1-5} heteroalkyl C_{3-6} cycloalkyl, and phenyl wherein when R_9 is Cl, NH_2 or OH it is not substituted on C_1 of the the alkyl to which it is attached;

R_{10} is independently selected from H, D, C_{1-4} alkyl, F, Cl, Br, OR_7, NHC(=O)OR_7, and NHC(=O)OR_7;

R_{11} is independently selected from CN, –C(=O)R_{12}, tetrazolyl,  , and  ;

R_{12} is independently selected from OH, OC_{1-4} alkyl, NH_2, $NHCH_2CH_2SO_3H$, and $NHSO_2C_{1-4}$alky;

r is independently selected from zero, 1, 2, 3, and 4.

5. The compound of claim 4 having Formula (III):



(III)

or an enantiomer, a diastereomer, a stereoisomer, a pharmaceutically acceptable salt thereof, wherein

R_2 is independently selected from CH_3 and CD_3;

R_{13} is independently selected from H and C_{1-4} alkyl;

R_3 is independently selected from H and C_{1-4} alkyl;

R_4 is independently selected from C_{1-6} alkyl substituted with 1-3 R_9, $-(CR_7R_7)_r-C_{3-6}$ cycloalkyl substituted with 1-3 R_8, and $-(CR_7R_7)_r$-aryl substituted with 1-3 R_8;

R_5 is independently selected from H, F, Cl, CN and C_{1-4} alkyl; provided one of R_5 is H;

R_6 is  ;

R_7 is independently selected from H, C_{1-4} alkyl, and C_{3-6} cycloalkyl; or R_7 and R_7, together with the carbon atom to which they both attach, form a C_{3-6} cycloalkyl ring;

R_8 is independently selected from H, C_{1-6} alkyl substituted with 1-5 R_9, C_{3-6} cycloalkyl, F, Cl, Br, CN, =O, and COOH;

R_9 is independently selected from H, F, Cl, NH_2, OH, OC_{1-5}alkyl, C_{1-5}alkyl, C_{3-6} cycloalkyl, and phenyl wherein when R_9 is Cl, NH_2 or OH it is not substituted on C_1 of the the alkyl to which it is attached;

R_{10} is independently selected from H, D, C_{1-4} alkyl, and F;

R_{11} is independently selected from CN, $-C(=O)R_{12}$, and tetrazolyl;

R_{12} is independently selected from OH, OC_{1-4} alkyl, NH_2, and $NHSO_2C_{1-4}$alky; and

r is independently selected from zero, 1, 2, 3, and 4.

6. The compound of claim 5, having Formula (IV):



(IV)

or an enantiomer, a diastereomer, a stereoisomer, a pharmaceutically acceptable salt thereof, wherein

R_2 is independently selected from CH_3 and CD_3;

R_{13} is independently selected from H and $C_{1\text{-}4}$ alkyl;

R_3 is independently selected from H and $C_{1\text{-}4}$ alkyl;

R_4 is independently selected from $C_{1\text{-}6}$ alkyl,



;

R_5 is independently selected from H, F, Cl, and $C_{1\text{-}4}$ alkyl; provided one of R_5 is H;

R_7 is independently selected from H, $C_{1\text{-}4}$ alkyl, and $C_{3\text{-}6}$ cycloalkyl;

R_8 is independently selected from H, $C_{1\text{-}6}$ alkyl substituted with 1-5 R_9, $C_{3\text{-}6}$ cycloalkyl, F, Cl, Br, CN, =O, and COOH;

R_9 is independently selected from H, F, Cl, NH_2, OH, $OC_{1\text{-}5}$alkyl, $C_{1\text{-}5}$alkyl, $C_{3\text{-}6}$ cycloalkyl, and phenyl wherein when R_9 is Cl, NH_2 or OH it is not substituted on C_1 of the the alkyl to which it is attached;

R_{10} is independently selected from H, D, $C_{1\text{-}4}$ alkyl, and F;

R_{11} is independently selected from CN, –C(=O)R_{12}, and  ; and

R_{12} is independently selected from OH and $NHSO_2C_{1-4}$alky.

7. The compound of claim 6 or an enantiomer, a diastereomer, a stereoisomer, a pharmaceutically acceptable salt thereof, wherein

R_4 is independently selected from



, and ; and

R_8 is independently selected from H, F, Cl, Br, CN, and C_{1-4} alkyl.

8. The compound of claim 7 having Formula (V):



(V)

or an enantiomer, a diastereomer, a stereoisomer, a pharmaceutically acceptable salt thereof, wherein

R_2 is independently selected from CH_3 and CD_3;

R_{13} is independently selected from H and CH_3;

R_3 is independently selected from H and CH_3;

R_4 is independently selected from



; and

R_5 is independently selected from H, F, and C_{1-4} alkyl;

R_8 is independently selected from H, F, Cl, Br, CN, and C_{1-4} alkyl;

R_{10} is independently selected from H, D, and F; and

R_{11} is independently selected from–C(=O)OH, and –C(=O)$NHSO_2Me$.

9. The compound of claim 7 having Formula (VI):



(VI)

or an enantiomer, a diastereomer, a stereoisomer, a pharmaceutically acceptable salt thereof, wherein

R_2 is independently selected from CH_3 and CD_3;

R_{13} is independently selected from H and CH_3;

R_3 is independently selected from H and CH_3;

R_4 is independently selected from



, and ;

R_5 is independently selected from H and CH_3; and

R_8 is independently selected from H, F, Cl, Br, CN, and C_{1-4} alkyl.

10. The compound of claim 4 having Formula (VII):



(VII)

or an enantiomer, a diastereomer, a stereoisomer, a pharmaceutically acceptable salt thereof, wherein

R_2 is independently selected from CH_3 and CD_3;

R_{13} is independently selected from H and C_{1-4} alkyl;

R_3 is independently selected from H and C_{1-4} alkyl;

R_4 is independently selected from C_{1-6} alkyl substituted with 1-3 R_9, $(CR_7R_7)_r$-C_{3-6} cycloalkyl substituted with 1-3 R_8, and -$(CR_7R_7)_r$-aryl substituted with 1-3 R_8;

R_5 is independently selected from H, F, Cl, CN, and C_{1-4} alkyl;

R_6 is  ;

R_7 is independently selected from H, C_{1-4} alkyl, and C_{3-6} cycloalkyl; or R_7 and $R_{7,}$ together with the carbon atom to which they both attach, form a C_{3-6} cycloalkyl ring;

R_8 is independently selected from H, C_{1-6} alkyl substituted with 1-5 R_9, C_{3-6} cycloalkyl, F, Cl, Br, CN, =O, and COOH;

R_9 is independently selected from H, F, Cl, NH_2, OH, OC_{1-5}alkyl, C_{1-5}alkyl, C_{3-6} cycloalkyl, and phenyl, wherein when R_9 is Cl, NH_2 or OH it is not substituted on C_1 of the the alkyl to which it is attached;

R_{10} is independently selected from H, C_{1-4} alkyl, and F;

R_{11} independently selected from–$C(=O)R_{12}$ and tetrazolyl;

R_{12} is independently selected from OH and $NHSO_2C_{1-4}$alky; and

r is independently selected from zero, 1, 2, 3, and 4.

11. The compound of claim 10, or an enantiomer, a diastereomer, a stereoisomer, a pharmaceutically acceptable salt thereof, wherein

R_2 is independently selected from CH_3 and CD_3;

R_{13} is independently selected from H and CH_3;

R_3 is independently selected from H and CH_3;

R_4 is independently selected from C_{1-6} alkyl, 

,



,



,



, and 

;

R_5 is independently selected from H, F, Cl, and C_{1-4} alkyl;

R_6 is



;

R_7 is independently selected from H, C_{1-4} alkyl, and C_{1-6} cycloalkyl; and

R_8 is independently selected from H, F, Cl, Br, CN, and C_{1-4} alkyl.

12. The compound of claim 10 having Formula (VIII):



(VIII)

or an enantiomer, a diastereomer, a stereoisomer, a pharmaceutically acceptable salt thereof, wherein

R_2 is independently selected from CH_3 and CD_3;

R_{13} is independently selected from H and CH_3;

R_3 is independently selected from H and CH_3;

R_4 is independently selected from



, and ;

R_5 is independently selected from H, F, and CH_3; and

R_8 is independently selected from H, F, Cl, Br, CN, and C_{1-4} alkyl.

13. The compound of claim 4 having Formula (IX):



(IX)

or an enantiomer, a diastereomer, a stereoisomer, a pharmaceutically acceptable salt thereof, wherein

R_2 is independently selected from CH_3 and CD_3;

R_{13} is independently selected from H and C_{1-4} alkyl;

R_3 is independently selected from H and C_{1-4} alkyl;

R_4 is independently selected from C_{1-6} alkyl substituted with 1-3 R_9, $(CR_7R_7)_r$-C_{3-6} cycloalkyl substituted with 1-3 R_8, and -$(CR_7R_7)_r$-aryl substituted with 1-3 R_8;

R_5 is independently selected from H, F, Cl, CN, and C_{1-4} alkyl;

R_6 is  ;

R_7 is independently selected from H, C_{1-4} alkyl, and C_{3-6} cycloalkyl; or R_7 and $R_{7,}$ together with the carbon atom to which they both attach, form a C_{3-6} cycloalkyl ring;

R_8 is independently selected from H, C_{1-6} alkyl substituted with 1-5 R_9, C_{3-6} cycloalkyl, F, Cl, Br, CN, =O, and COOH;

R_9 is independently selected from H, F, Cl, NH_2, OH, OC_{1-5}alkyl, C_{1-5}alkyl, C_{3-6} cycloalkyl, and phenyl, wherein when R_9 is Cl, NH_2 or OH it is not substituted on C_1 of the the alkyl to which it is attached;

R_{10} is independently selected from H and F;

R_{11} is independently selected from–C(=O)R_{12} and tetrazolyl;

R_{12} is independently selected from OH and –C(=O)$NHSO_2Me$; and

r is independently selected from zero, 1, 2, 3, and 4.

14. The compound of claim 4, wherein said compound is selected from the group of:


,

,

,

,

,

,

,

 ,  ,  ,

 ,  ,  ,

 ,  ,  ,

 , or an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

15. The compound of claim 4, wherein said compound is selected from the group of:


,

,

,

,


,

,

,

,



, and 

, or an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

16. The compound of anyone of claims 1-8, wherein said compound has the formula:



, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

17. The compound of anyone of claims 1-8, wherein said compound has the formula:



, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

18. The compound of anyone of claims 1-8, wherein said compound has the formula:


, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

19. The compound of anyone of claims 1-8, wherein said compound has the formula:


, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

20. The compound of anyone of claims 1-8, wherein said compound has the formula:


, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

21. The compound of anyone of claims 1-8, wherein said compound has the formula:



, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

22. The compound of anyone of claims 1-8, wherein said compound has the formula:



, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

23. The compound of anyone of claims 1-8, wherein said compound has the formula:



, or an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

24. The compound of anyone of claims 1-8, wherein said compound has the formula:



, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

25. The compound of anyone of claims 1-8, wherein said compound has the formula:



, an enantiomer, a diastereomer, a stereoisomer, or a pharmaceutically acceptable salt thereof.

26. A compound of Formula (X):



(X)

or an enantiomer, a diastereomer, or a stereoisomer thereof, wherein

R_{20} is independently C_{1-6} alkyl or H;

R_{21} is independently C_{1-6} alkyl or H;

X^5 and X^6 are independently CH or N; and

X^7 is Br.

27. The compound of claim 26 having Formula (XI):



(XI), or an enantiomer, a diastereomer, or a stereoisomer thereof.

28. A pharmaceutical composition comprising one or more compounds according to anyone of claims 1-25 and a pharmaceutically acceptable carrier or diluent.

29. A compound according to any one of claims 1-25 for use in therapy.

30. A compound according to any one of claims 1-25 or a pharmaceutically acceptable salt thereof for use in treating fibrosis in a mammal in need thereof.

31. A compound according to any one of claims 1-25 or a pharmaceutically acceptable salt thereof for use in treating lung fibrosis (idiopathic pulmonary fibrosis), asthma, chronic obstructive pulmonary disease (COPD), renal fibrosis, acute kidney injury, chronic kidney disease, liver fibrosis (non-alcoholic steatohepatitis), skin fibrosis, fibrosis of the gut, breast cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, bone cancer, colon cancer, bowel cancer, head and neck cancer, melanoma,

multiple myeloma, chronic lymphocytic leukemia, cancer pain, tumor metastasis, transplant organ rejection, scleroderma, ocular fibrosis, age related macular degeneration (AMD), diabetic retinopathy, collagen vascular disease, atherosclerosis, Raynaud's phenomenon, or neuropathic pain in a mammal in need thereof.

5